Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors

  • End date
    Mar 17, 2026
  • participants needed
  • sponsor
Updated on 17 May 2022
monoclonal antibodies
interleukin 2


This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.


The phase 1a portion of the study will evaluate STK-012 monotherapy administered subcutaneously weekly alone and in combination with pembrolizumab administered every 3 weeks intravenously in a standard 3+3 dose-escalation study design. Patients with selected solid tumor types will be enrolled who have progressed after standard of care treatments. The phase 1b dose expansion will evaluate STK-012 at the recommended phase 2 dose in combination with pembrolizumab in selected solid tumor types.

Condition Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Ovarian Cancer, Cervical Cancer, Microsatellite Instability High
Treatment Pembrolizumab, STK-012
Clinical Study IdentifierNCT05098132
Last Modified on17 May 2022


Yes No Not Sure

Inclusion Criteria

In dose-escalation (Phase 1a), patients must have selected tumor types and must have progressed after standard of care treatment, or be intolerant to treatment, or refused standard treatment
Available archived tumor tissue sample. In the setting where archival material is unavailable or unsuitable for use, the patient must consent and undergo fresh tumor biopsy. In some patients, a new pre-treatment and on-treatment tumor biopsy may be required
Patients with central nervous system (CNS) metastases must have been treated and be asymptomatic

Exclusion Criteria

Received systemic anti-cancer therapy within 3 weeks of the first dose of study treatment or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment
Received definitive radiotherapy within 2 weeks of the first dose of study treatment; or palliative radiotherapy (< 2 weeks of radiotherapy to non-central nervous system [CNS] disease) within 1 week of the first dose of study treatment
Received prior IL-2-based or IL-15-based cytokine therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note